drugset / Trial / NCT00003380

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00003380

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin and etoposide in treating patients who have recurrent or persistent ovarian, fallopian tube, or peritoneal cancer.

Timeline

Start
1998-05
Primary completion
2002-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified Intravenous
Subject Etoposide Small molecule Oral